Cover Image
市場調查報告書

歐洲的生技仿製藥市場上機會的展望 2020年

Europe Biosimilars Market Opportunity Outlook 2020

出版商 KuicK Research 商品編碼 344795
出版日期 內容資訊 英文 310 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
歐洲的生技仿製藥市場上機會的展望 2020年 Europe Biosimilars Market Opportunity Outlook 2020
出版日期: 2015年11月09日 內容資訊: 英文 310 Pages
簡介

本報告提供歐洲的生技仿製藥市場相關調查分析、市場展望、各國市場趨勢分析、各市場區隔的市場概要、臨床/非臨床指南、各國家/企業/適應症/相位的臨床實驗平台、已上市產品分析等系統性資訊。

第1章 歐洲的生技仿製藥市場展望

  • 市場概要
  • 歐洲臨床實驗的生技仿製藥

第2章 歐洲的生技仿製藥市場趨勢分析:各國

  • 奧地利
  • 比利時
  • 法國
  • 德國
  • 匈牙利
  • 義大利
  • 挪威
  • 波蘭
  • 西班牙
  • 瑞典
  • 瑞士
  • 英國

第3章 歐洲的生技仿製藥的簡介:各種類

  • 生長激素
  • 紅血球產生素
  • G-CSF
  • 單克隆工程
  • 促濾泡素
  • 胰島素

第4章 歐洲的生技仿製藥的風險管理規劃 & 安全法規情形

第5章 歐洲的生技仿製藥市場動態

  • 有利的指標
  • 阻礙成長要素

第6章 歐洲的生技仿製藥市場未來展望

第7章 歐洲的生技仿製藥市場法規結構

第8章 歐洲的生技仿製藥開發臨床 & 非臨床指南

第9章 歐洲的生技仿製藥的臨床實驗平台:各國家、企業、適應症及相位

  • 不明
  • 研究階段
  • 前臨床階段
  • 臨床階段
  • 第一階段
  • 第二階段
  • 第三階段
  • 申請完畢
  • 已透過核准

第10章 歐洲的已上市生技仿製藥臨床考察

  • 紅血球產生素Alpha生技仿製藥 (Sandoz)
  • 紅血球產生素Alpha生技仿製藥 (Wockhardt)
  • 紅血球產生素Theta生技仿製藥 (Teva Pharmaceutical)
  • 紅血球產生素Zeta (Hospira ,STADA Arzneimittel)
  • Filgrastim生技仿製藥 (CT Arzneimittel)
  • Filgrastim生技仿製藥 (Hexal)
  • Filgrastim生技仿製藥 (Hospira)
  • Filgrastim生技仿製藥 (Ratiopharm/Teva)
  • Filgrastim生技仿製藥 (Sandoz)
  • 促濾泡素Alpha生技仿製藥 (Teva)
  • Infliximab (Janssen Biotech)
  • Infliximab生技仿製藥 (Celltrion)
  • 胰島素生技仿製藥 (Wockhardt)
  • 胰島素懸浮液低精蛋白生物仿製藥 (Wockhardt)
  • 胰島素/胰島素懸浮液低精蛋白生物仿製藥 (Wockhardt)
  • Lipegfilgrastim (Teva Pharmaceutical)
  • Peginterferon Alfa-2a(Roche)
  • Peginterferon Alfa-2b (Merck Sharp & Dohme)
  • 生長激素生技仿製藥 (Sandoz)
  • Trastuzumab (Genentech)

第11章 開發中斷/中止的生技仿製藥臨床考察

  • 沒有開發報告
  • 中斷

第12章 競爭情形

  • Alvotech
  • Allergan
  • Amgen
  • Biocad
  • Bio-Ker
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Cerbios Pharma
  • Celltrion
  • Gedeon Richter
  • Genentech
  • Genexine
  • Glycotope
  • Harvest Moon Pharmaceuticals
  • Hospira
  • Janssen Biotech
  • LFB Biotechnologies
  • Mabion
  • mAbxience
  • Merck
  • Momenta Pharmaceuticals
  • Novartis
  • Perosphere
  • Pfizer
  • Reliance Life Sciences
  • Roche
  • R-Pharm
  • Samsung Bioepis
  • Sanofi
  • Teva Pharmaceutical
  • Wockhardt
目錄

Burgeoning pressure on healthcare system has caused the regulators across the globe to look for suitable therapeutic options. Biologic drugs are commonly used for treatment of various diseases but they are costly and their alternative options are difficult to find. Biosimilars have come forth as new modality having lesser cost with equivalent therapeutic efficacy like biologics. They are introduced in market after patent expiry of biologics and Europe became the first market to allow commercialization of biosimilars. European Commission (EC) passed legislation in 2004 creating approval pathway (Directive 2001/83/EC Directive 2004/27/EC) for biosimilars. European Medicines Agency (EMA) approved first biosimilar in 2006, since then several biosimilars have been introduced in European market owing to applicability in numerous indications and higher cost arbitrage. In this way, European nations are expected to relieve burden from their healthcare system with the help of biosimilars.

Safety and efficacy are main concerns with biosimilars; EMA requires head-to-head comparison for ensuring pharmacological parameters. Ensuring similarity or high similarity in bioanalytical way decreases market winding time. Consequently, clinical trials could be conducted with higher confidence levels to ensure patient safety. Many biosimilars belonging to different categories for different indications has been introduced in past years. They have been able to erode profit margins of biologics in past decades. Wide acceptance could also be observed leading to higher prescription for biosimilars as compared to biologics. This scenario shows that biosimilars developers will have lots of commercialization opportunities in European market.

Biosimilars have been introduced for several disease categories offering myriad of options to the patients. Cancer supportive therapies have large consumer base due to which associated biosimilars are in high demand. Filgrastim and Erythropoietins biosimilars are one of the widely used products in European market. These well-established segments have numbers of products as compared to other disease categories. Biosimilar monoclonal antibodies are in high demand as they have high safety and efficacy along with minimized side effects. Their cost is also lesser as compared to biologic monoclonal antibodies. Besides this, biosimilar insulin has also been introduced which have capability to generate significant revenues. Biosimilar insulin has created as new segment due to which more biosimilar products are expected to enter in coming years. In this way, European biosimilars market shows diverse categories and opportunities to venture in newly developed segments.

Extrapolation of biosimilars is allowed after establishing significant comparability with reference biologics. Depending on quality profile they are approved by EMA and biosimilar developers have to submit Risk Management Plan (RMP). This measure ensures that biosimilars entering in European market are harmless. Biosimilar developers from developing countries find it difficult to enter in European market as their fall short of EMA's standards. On the other hand, outsourced biosimilars products showing compliance with EMA's norms are allowed for commercialization. In this way, biosimilar developers from under developing countries find Europe as a suitable market place. Their competitive prices and highly developed manufacturing capabilities have also contributed in growth of European biosimilars market.

"Europe Biosimilars Market Opportunity Outlook 2020" Report Highlight:

  • Europe Biosimilars Market Outlook
  • Europe Biosimilars Market Trend Analysis by Country
  • Introduction of Biosimilars in European Market by Segment
  • Clinical & Non Clinical Guidelines
  • Europe Biosimilar Clinical Pipeline by Country, Company, Indication & Phase
  • Europe Biosimilar Clinical Pipeline: 109 Biosimilars
  • Clinical Insight of Biosimilars Marketed in Europe
  • Marketed Biosimilars in Europe: 20 Biosimilars

Table of Contents

1. Europe Biosimilars Market Outlook

  • 1.1 Market Overview
  • 1.2 Biosimilars in Clinical Trials in Europe

2. Europe Biosimilars Market Trend Analysis by Country

  • 2.1 Austria
  • 2.2 Belgium
  • 2.3 France
  • 2.4 Germany
  • 2.5 Hungary
  • 2.6 Italy
  • 2.7 Norway
  • 2.8 Poland
  • 2.9 Spain
  • 2.10 Sweden
  • 2.11 Switzerland
  • 2.12 UK

3. Introduction of Biosimilars in European Market by Segment

  • 3.1 Growth Hormones (2006)
  • 3.2 Epoetin (2007)
  • 3.3 G-CSF (2008)
  • 3.4 Monoclonal Antibodies (2013)
  • 3.5 Follitropin (2013)
  • 3.6 Insulin (2015)

4. Europe Biosimilars Risk Management Planning & Safety Regulation Scenario

5. Europe Biosimilars Market Dynamics

  • 5.1 Favorable Parameters
  • 5.2 Growth Inhibitors

6. Europe Biosimilars Market Future Outlook

7. Europe Biosmilars Market Regulatory Framework

8. Clinical & Non Clinical Guideline For Development of Biosimilars in Europe

  • 8.1 Development of Similar Biological Medicinal Products Containing r-hFSH
  • 8.2 Similar Biological Medicinal Products Containing Interferon Beta
  • 8.3 Immunogenicity Assessment of Monoclonal Antibodies Intended For In Vivo Clinical Use
  • 8.4 Similar Biological Medicinal Products Containing Monoclonal Antibodies
  • 8.5 Similar Biological Medicinal Products Containing Recombinant Erythropoietins
  • 8.6 Similar Medicinal Products Containing Recombinant Human Soluble Insulin
  • 8.7 Similar Medicinal Products Containing Somatropin
  • 8.8 Similar Biological Medicinal Products Containing Biotechnology Derived Proteins as Active Substance
  • 8.9 Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins
  • 8.10 Comparability of Biotechnology-Derived Medicinal Products After A Change In The Manufacturing Process

9. Europe Biosimilar Clinical Pipeline by Country, Company, Indication & Phase

  • 9.1 Unknown
  • 9.2 Research
  • 9.3 Preclinical
  • 9.4 Clinical
  • 9.5 Phase-I
  • 9.6 Phase-II
  • 9.7 Phase-III
  • 9.8 Preregistration
  • 9.9 Registered

10. Clinical Insight of Biosimilars Marketed in Europe

  • 10.1 Epoetin Alfa Biosimilar (Sandoz)
  • 10.2 Epoetin Alfa Biosimilar (Wockhardt)
  • 10.3 Epoetin Theta Biosimilar (Teva Pharmaceutical)
  • 10.4 Epoetin Zeta (Hospira ,STADA Arzneimittel)
  • 10.5 Filgrastim Biosimilar (CT Arzneimittel)
  • 10.6 Filgrastim Biosimilar (Hexal)
  • 10.7 Filgrastim Biosimilar (Hospira)
  • 10.8 Filgrastim Biosimilar (Ratiopharm/Teva)
  • 10.9 Filgrastim Biosimilar (Sandoz)
  • 10.10 Follitropin Alfa Biosimilar (Teva)
  • 10.11 Infliximab (Janssen Biotech)
  • 10.12 Infliximab Biosimilar (Celltrion)
  • 10.13 Insulin Biosimilar (Wockhardt)
  • 10.14 Insulin Suspension Isophane Biosimilar (Wockhardt)
  • 10.15 Insulin/Insulin Suspension Isophane Biosimilar (Wockhardt)
  • 10.16 Lipegfilgrastim (Teva Pharmaceutical)
  • 10.17 Peginterferon Alfa-2a (Roche)
  • 10.18 Peginterferon Alfa-2b (Merck Sharp & Dohme)
  • 10.19 Somatropin Biosimilar (Sandoz)
  • 10.20 Trastuzumab (Genentech)

11. Suspended & Discontinued Biosimilars Clinical Insight

  • 11.1 No Development Reported
  • 11.2 Discontinued

12. Competive Landscape

  • 12.1 Alvotech
  • 12.2 Allergan
  • 12.3 Amgen
  • 12.4 Biocad
  • 12.5 Bio-Ker
  • 12.6 BioXpress Therapeutics
  • 12.7 Boehringer Ingelheim
  • 12.8 Cerbios Pharma
  • 12.9 Celltrion
  • 12.10 Gedeon Richter
  • 12.11 Genentech
  • 12.12 Genexine
  • 12.13 Glycotope
  • 12.14 Harvest Moon Pharmaceuticals
  • 12.15 Hospira
  • 12.16 Janssen Biotech
  • 12.17 LFB Biotechnologies
  • 12.18 Mabion
  • 12.19 mAbxience
  • 12.20 Merck
  • 12.21 Momenta Pharmaceuticals
  • 12.22 Novartis
  • 12.23 Perosphere
  • 12.24 Pfizer
  • 12.25 Reliance Life Sciences
  • 12.26 Roche
  • 12.27 R-Pharm
  • 12.28 Samsung Bioepis
  • 12.29 Sanofi
  • 12.30 Teva Pharmaceutical
  • 12.31 Wockhardt
Back to Top